BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35304348)

  • 1. Stricter Postoperative Oropharyngeal Cancer Radiation Therapy Normal Tissue Dose Constraints Are Feasible.
    Su W; Wright CM; Lee DY; Kim M; Anstadt EJ; Teo BK; Carlson DJ; Lukens JN; Eisbruch A; Lin A
    Pract Radiat Oncol; 2022; 12(4):e282-e285. PubMed ID: 35304348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Quantitative Clinical Decision-Support Strategy Identifying Which Patients With Oropharyngeal Head and Neck Cancer May Benefit the Most From Proton Radiation Therapy.
    Brodin NP; Kabarriti R; Pankuch M; Schechter CB; Gondi V; Kalnicki S; Guha C; Garg MK; Tomé WA
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):540-552. PubMed ID: 30496877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using a reduced spot size for intensity-modulated proton therapy potentially improves salivary gland-sparing in oropharyngeal cancer.
    van de Water TA; Lomax AJ; Bijl HP; Schilstra C; Hug EB; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e313-9. PubMed ID: 21708427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Model-Based Approach to Predict Short-Term Toxicity Benefits With Proton Therapy for Oropharyngeal Cancer.
    Rwigema JM; Langendijk JA; Paul van der Laan H; Lukens JN; Swisher-McClure SD; Lin A
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):553-562. PubMed ID: 30625409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methods for Reducing Normal Tissue Complication Probabilities in Oropharyngeal Cancer: Dose Reduction or Planning Target Volume Elimination.
    Samuels SE; Eisbruch A; Vineberg K; Lee J; Lee C; Matuszak MM; Ten Haken RK; Brock KK
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):645-52. PubMed ID: 27681761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of submandibular gland and swallowing structure sparing to post-radiation therapy PEG dependence in oropharynx cancer patients treated with split-neck IMRT technique.
    Gensheimer MF; Nyflot M; Laramore GE; Liao JJ; Parvathaneni U
    Radiat Oncol; 2016 Nov; 11(1):151. PubMed ID: 27846899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome after pencil beam scanning proton therapy and dysphagia/xerostomia NTCP calculations of proton and photon radiotherapy delivered to patients with cancer of the major salivary glands.
    Walser MA; Bachmann N; Kluckert J; Köthe A; Tully C; Leiser D; Lomax AJ; Bizzocchi N; Langendijk JA; Weber DC
    Br J Radiol; 2023 Aug; 96(1148):20220672. PubMed ID: 37129312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NTCP modelling of xerostomia after radiotherapy for oropharyngeal cancer using the PRO-CTCAE and CTCAE scoring systems at different time-points post-RT.
    Tzikas A; Lavdas E; Kehagias D; Amdur R; Mendenhall W; Sheets N; Green R; Chera B; Mavroidis P
    Phys Med; 2023 Dec; 116():103169. PubMed ID: 37989042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parotid glands dose-effect relationships based on their actually delivered doses: implications for adaptive replanning in radiation therapy of head-and-neck cancer.
    Hunter KU; Fernandes LL; Vineberg KA; McShan D; Antonuk AE; Cornwall C; Feng M; Schipper MJ; Balter JM; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):676-82. PubMed ID: 24035328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential of intensity-modulated proton radiotherapy to reduce swallowing dysfunction in the treatment of head and neck cancer: A planning comparative study.
    van der Laan HP; van de Water TA; van Herpt HE; Christianen ME; Bijl HP; Korevaar EW; Rasch CR; van 't Veld AA; van der Schaaf A; Schilstra C; Langendijk JA;
    Acta Oncol; 2013 Apr; 52(3):561-9. PubMed ID: 22708528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes.
    Gensheimer MF; Liao JJ; Garden AS; Laramore GE; Parvathaneni U
    Radiat Oncol; 2014 Nov; 9():255. PubMed ID: 25424729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of oral mucosa dose and volume parameters with Grade 3 mucositis, in patients treated with volumetric modulated arc radiotherapy for oropharyngeal cancer?
    Bansal A; Bedi N; Kaur R; Singh G; Benipal RPS; Dangwal V
    Jpn J Clin Oncol; 2023 Mar; 53(4):313-320. PubMed ID: 36546704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Use of A Priori Knowledge of Organ-At-Risk Sparing During Radiation Therapy Treatment for Oropharyngeal Cancer: Dosimetric and Patient Reported Outcome Improvements.
    Fried DV; Das SK; Marks LB; Chera BS
    Pract Radiat Oncol; 2022; 12(3):e193-e200. PubMed ID: 34958985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation.
    Grills IS; Yan D; Martinez AA; Vicini FA; Wong JW; Kestin LL
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):875-90. PubMed ID: 14529795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between plan quality improvements and reduced acute dysphagia and xerostomia in the definitive treatment of oropharyngeal squamous cell carcinoma.
    Cui T; Ward MC; Joshi NP; Woody NM; Murray EJ; Potter J; Dorfmeyer AA; Greskovich JF; Koyfman SA; Xia P
    Head Neck; 2019 Apr; 41(4):1096-1103. PubMed ID: 30702180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-volume toxicity modeling for de-intensified chemo-radiation therapy for HPV-positive oropharynx cancer.
    Mavroidis P; Price A; Fried D; Kostich M; Amdur R; Mendenhall W; Liu C; Das S; Marks LB; Chera B
    Radiother Oncol; 2017 Aug; 124(2):240-247. PubMed ID: 28712533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-Field Sequential Intensity-Modulated Radiotherapy for Local-Regional Advanced Head-and-Neck Squamous Cell Carcinoma.
    Refaat T; Choi M; Thomas TO; Bacchus I; Agulnik M; Pelzer HJ; Mellott AL; Rademaker AW; Liu D; Sathiaseelan V; Mittal BB
    Am J Clin Oncol; 2015 Dec; 38(6):588-94. PubMed ID: 24136140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sparing bilateral neck level IB in oropharyngeal carcinoma and xerostomia outcomes.
    Tam M; Riaz N; Kannarunimit D; Peña AP; Schupak KD; Gelblum DY; Wolden SL; Rao S; Lee NY
    Am J Clin Oncol; 2015 Aug; 38(4):343-7. PubMed ID: 26208401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of neck dissection in N2-3 oropharyngeal squamous cell carcinomas treated with definitive chemoradiotherapy: An observational real-life study].
    Klausner G; Troussier I; Kreps S; Fabiano E; Laccourreye O; Giraud P
    Cancer Radiother; 2021 Dec; 25(8):771-778. PubMed ID: 34175226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.